In this episode of Thinking Thoracic, Dr. Jane Yanagawa talks with Dr. Stephanie Worrell, clinical associate professor and thoracic section chief, division of cardiothoracic surgery, University of Arizona, about her expertise in esophageal perforation management. Hear how esophageal surgery can involve complications such as anastomotic leak, pain, bleeding, infection, and reflux and how surgeons can best handle them. 

25 minutes

A traveling, mobile lung screening program has the potential to diagnose cancer earlier, leading to a higher cure rate and lower death rate. In this episode of Thinking Thoracic, STS’s new podcast series, host Dr. Jeffrey Yang talks with Dr. Robert Headrick about CHI Memorial’s “Breathe Easy” mobile lung screening program and how meeting people where they are with quality healthcare services like this one is saving lives.

40 mins

In this first episode of Thinking Thoracic, podcast host Dr. Erin Gillaspie talks with Dr. Wade Iams about notable takeaways on key clinical trials presented at the 2024 World Conference on Lung Cancer and how these findings will help shape the thoracic surgery landscape. They share proactive steps on enhancing relationships within a multidisciplinary lung cancer care team and improving handoffs between specialties like surgery, medical oncology, and radiation.

40 mins

CHICAGO, IL – October 17, 2024 – The Society of Thoracic Surgeons (STS) announces the release of two new risk calculators to inform physician-patient decision-making in thoracic surgery. Engineered using contemporary data from the STS General Thoracic Surgery Database, these interactive tools provide surgeons with accurate, preoperative risk estimations for outcomes of esophagectomy for cancer and pulmonary resection for lung cancer. 

Oct 23, 2024
In Spanish with English subtitles. 
Date
Duration
1 hr. 37 min.

In the past five years, immunotherapy has transformed the approach to treating resectable lung cancer in both neoadjuvant and adjuvant settings. During this webinar, experts will explore the continued importance of radiation therapy in managing resectable lung cancer and highlight essential insights that thoracic surgeons need for daily practice.  

Sponsored by AstraZeneca

 

Moderators

Nathaniel R. Evans III, MD
Thomas Jefferson University
Philadelphia, PA

Date
Duration
58 min.

Circulating tumor DNA (ctDNA) is a blood test that can be used to detect and monitor thoracic malignancies. It is being used to detect mutations, monitor for recurrence after surgery and other treatments, and can even be used in conjunction with screening to help identify malignancy. As the field continues to advance, it is crucial for thoracic surgeons, trainees, and healthcare providers to stay informed about the latest developments in ctDNA testing and its applications for thoracic patients.

Sponsored by AstraZeneca

 

Date
Duration
1 hr.

Two papers recently published in The Annals of Thoracic Surgery aim to guide the management of thymoma1 and pleural drains following pulmonary lobectomy2 – thoracic conditions and treatments that lack widely accepted guidelines. Recognizing this need, the Society of Thoracic Surgeons (STS) Workforce on Evidenced-Based Surgery convened a task force to develop expert consensus documents to help alleviate this knowledge gap.

Thymoma, a rare epithelial tumor – but also the most common anterior mediastinal tumor in adult patients – is a condition thoracic surgeons will likely encounter as clinicians. However, there is a lack of evidence covering all aspects of treatment due to its relatively low incidence. Managing pleural drains following pulmonary lobectomy is standard practice, yet there are no established guidelines on this topic despite abundant published literature.

Management of thymoma

The STS Workforce on Evidence-Based Surgery, which includes general thoracic surgeons with expertise in thoracic surgical oncology, and medical and radiation oncologists with expertise in neoadjuvant and adjuvant therapies, evaluated existing literature about surgical considerations in managing thymomas, such as:

•    Imaging characteristics
•    Diagnostic tests 
•    Staging 
•    Surgical approach and technique
•    Neoadjuvant and adjuvant therapy 
•    Surgery for advanced or recurrent disease, and 
•    Postoperative surveillance

Consensus statements were drafted using the modified Delphi method. Votes for each proposed statement were tallied using a 5-point Likert scale, with the option to abstain on those not within the specific authors’ expertise. Statements with 75% of responding authors selecting “agree” or “strongly agree” were considered to have reached a consensus. 

Unlike broader guidelines encompassing various aspects of thymoma management, including medical oncology, radiology, and pathology, this paper addresses thymoma from a surgical perspective by guiding surgical interventions, especially in metastatic and recurrent diseases.

"Given the scarcity of randomized controlled trials due to the rarity of thymoma, this document is framed as an expert consensus rather than strict evidence-based clinical practice guidelines," said the study's lead author, Dr. Douglas Liou, clinical associate professor at Stanford Medicine. "Our findings rely more heavily on the combined experience and judgment of experts in the field rather than solely on data from large-scale studies." 

Read the Annals article

Management of pleural drains following pulmonary lobectomy

Similarly, the consensus document developed by the STS Workforce on Evidence-Based Surgery to manage pleural drains includes:

•    Choice of drain, including size, type, and number
•    Management, such as use of suction versus waterseal and criteria for removal
•    Imaging recommendations, including the use of daily and post-pull chest x-rays
•    Use of digital drainage systems, and
•    Management of prolonged air leak

Workforce members reviewed existing literature on the condition. A consensus using a modified Delphi method consisting of two rounds of voting until 75% agreement on the statements was reached, with a total of thirteen statements that encouraged standardization and stimulated additional research in this critical area. 

“Optimal management of these drains should reduce patient discomfort, length of stay, and complications.”  said study investigator Dr. Michael Kent, associate professor of surgery at Harvard Medical School. “However, despite how commonly chest tubes are used in practice, the literature must provide more clarity on this subject. Many important questions have yet to be addressed and may require well-designed, prospective randomized trials.”

Read the Annals article

1. Reference: Liou DZ, Berry MF, Brown LM, Demmy TL, Huang J, Khullar OV, Padda SK, Shah RD, Taylor MD, Toker SA, Weiss E, Wightman SC, Worrell SG, Hayanga JWA, The Society of Thoracic Surgeons Expert Consensus Document on the Surgical Management of Thymomas, The Annals of Thoracic Surgery (2024)

2. Reference: Kent MS, Mitzman B, Diaz-Gutierrez, I, Khullar OV, Fernando H, Backus L, Brunelli A, Cassivi SD, Cerfolio RJ, Crabtree TD, Kakuturu J, Martin LW, Worrell SG, Raymond DP, Schumacher L, Hayanaga JWA, The Society of Thoracic Surgeons Expert Consensus Document on the Management of Pleural Drains following Pulmonary Lobectomy, The Annals of Thoracic Surgery (2024)

Jul 25, 2024
3 min read

In this video in the 8 in 8 Series, Dr. Dwight Owen (Ohio State University) discussed advances in biomarker testing and neoadjuvant immunotherapy for resectable non-small cell lung cancer. The talk includes a look at the role of PD-L1 testing, peri-operative chemo-immunotherapy, and the importance of NGS testing for patients with actionable mutations.

Supported by AstraZeneca.

Duration
7 min.

In this 8 in 8 video, Dr. Jessica Donington provides an update on adjuvant and neoadjuvant clinical trials that have recently concluded or will be releasing data in the near future. She reviews patient populations, methodology, and implications of trial findings for the treatment of resectable lung cancer.

Presenter: 

Jessica S. Donington, MD, MSCR
University of Chicago Medicine & Biological Sciences
Chicago, IL

Supported by AstraZeneca

Duration
11 min